scholarly journals Interventional heart failure therapy: A new concept fighting against heart failure

Author(s):  
Keita Saku ◽  
Shohei Yokota ◽  
Takuya Nishikawa ◽  
Koichiro Kinugawa
2020 ◽  
Vol 13 (12) ◽  
pp. e238047
Author(s):  
Alicia Lefas ◽  
Neil Bodagh ◽  
Jiliu Pan ◽  
Ali Vazir

We describe the case of an 86-year-old man with a background of severe left ventricular dysfunction and ischaemic cardiomyopathy who, having been optimised for heart failure therapy in hospital, unexpectedly deteriorated again with hypotension and progressive renal failure over the course of 2 days. Common causes of decompensation were ruled out and a bedside echocardiogram unexpectedly diagnosed new pericardial effusion with tamponade physiology. The patient underwent urgent pericardiocentesis and 890 mL of haemorrhagic fluid was drained. Common causes for haemopericardium were ruled out, and the spontaneous haemopericardium was thought to be related to introduction of rivaroxaban anticoagulation. The patient made a full recovery and was well 2 months following discharge. This case highlights the challenges of diagnosing cardiac tamponade in the presence of more common disorders that share similar non-specific clinical features. In addition, this case adds to growing evidence that therapy with direct oral anticoagulants can be complicated by spontaneous haemopericardium, especially when coadministered with other agents that affect clotting, renal dysfunction and cytochrome P3A5 inhibitors.


2008 ◽  
Vol 14 (6) ◽  
pp. S100
Author(s):  
Amandeep S. Dhaliwal ◽  
Blaise Carabello ◽  
Audrius Bredikis ◽  
Gabriel Habib ◽  
Kumudha Ramasubbu ◽  
...  

The Lancet ◽  
2016 ◽  
Vol 387 (10017) ◽  
pp. 408-410 ◽  
Author(s):  
Nikolaos Dagres ◽  
Gerhard Hindricks

2016 ◽  
Vol 51 (1) ◽  
pp. 79-82
Author(s):  
Douglas L. Jennings

Heart failure (HF) continues to afflict millions of Americans, resulting in substantial clinical and economic burden to our society. Recent literature has highlighted the role of 2 novel therapies (an angiotensin receptor blocker/neprilysin inhibitor and ivabradine) in further reducing residual disease in HF. Simultaneously, evidence has mounted suggesting that older therapies like digoxin are not effective in contemporary practice and, in fact, may be harmful. This editorial summarizes the most recently published articles pertaining to both new and old HF therapies and provides a call to action to pharmacists on how to shift patients toward effective drug regimens.


2007 ◽  
Vol 30 (6) ◽  
pp. 301-305 ◽  
Author(s):  
Josep Lupón ◽  
Agustín Urrutia ◽  
Beatriz González ◽  
Crisanto Díez ◽  
Salvador Altimir ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document